Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05234866 · ClinicalTrials.gov registry record
Paradoxical Lucidity in Severe End-Stage Dementia
A clinical trial of Dementia, sponsored by NYU Langone Health.
- Recruiting
- Registry status
- 520
- Enrollment target
- 1
- Study location
NCT05234866: Recruiting study of Dementia, sponsored by NYU Langone Health.
NCT05234866 is a study of Dementia that is actively recruiting participants, run by NYU Langone Health. The registered enrollment target is 520 participants, below the 7,720-participant average among 199 other Dementia trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05234866, a study of Dementia, is actively recruiting participants, sponsored by NYU Langone Health.
- RECRUITING
- Registry status
- 520 participants
- Enrollment target
- 1
- Study location
Study Summary
Cognitive decline in dementia is considered irreversible, however episodes of paradoxical lucidity (PL) in severe dementia suggest other mechanisms may be in play. Beyond anecdotal reports of transient PL events occurring in patients predominantly in late-stage dementia and typically lasting anywhere from a few minutes to several hours, little is known about PL. The study team proposes to develop and conduct a mixed methods prospective study of PL during end stage advanced dementia, creating a definition and measurement scale for PL in advanced dementia, and identifying the potential electro cortical biomarkers of PL in advanced dementia. This study will be divided in two phases: Phase I and Phase II. During Phase I, the study team will collect sufficient and necessary data through an online survey and focus groups as well as assess the safety and feasibility of using symptom diaries (also known as daily trackers or journals) and real-time video EEG monitoring (vEEG). After preliminary review of the study procedures, the PI will decide whether to move onto the Phase II. The second phase will aim to expand the study population and refine study methods as well as create a definition and measurement scale for PL in advances dementia.
Conditions Studied
Study Locations (1)
New York
- NYU Langone Health - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 520 participants |
| Start Date | 2022-06-02 |
| Est. Completion | 2026-05-31 |
What NCT05234866 shows while recruiting
NCT05234866 is an observational study that tracks outcomes without assigning an intervention. The registered 520 participants enrollment target is mid-sized for trials with a published cap, below the 7,720-participant average among 199 other Dementia trials with a reported enrollment target (93% lower).
The record links to 1 condition, with Dementia appearing as the primary indexed condition, and to 0 interventions.
NCT05234866 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT05234866 about?
NCT05234866 is a clinical study titled "Paradoxical Lucidity in Severe End-Stage Dementia". Cognitive decline in dementia is considered irreversible, however episodes of paradoxical lucidity (PL) in severe dementia suggest other mechanisms may be in play. Beyond anecdotal reports of transient PL events occurring in patients predominantly in late-stage dementia and typically lasting anywher...
What is the current status of trial NCT05234866?
This trial is currently recruiting. The enrollment target is 520 participants. The study started on 2022-06-02. Estimated completion is 2026-05-31.
What conditions does trial NCT05234866 study?
This clinical trial studies the following conditions: Dementia.
Who is sponsoring clinical trial NCT05234866?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05234866 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dementia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05234866's enrollment target sits among peer trials
520 47th of 199 higher than 153 of 199 other Dementia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Dementia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Dynamic Light Scattering Ocular Measurement in the Detection of Dementia
RECRUITING
-
Ferritin and Iron Burden in SAH sIRB
RECRUITING · Phase 1
-
δ in Dementia Clinical Trials
RECRUITING · NA
-
Door-Through-Door Companion Rideshare Technology for Individuals With Alzheimer's Disease and Related Dementias (AD/ADRD)
RECRUITING · Phase 1
-
Caregiver as Navigator: Develop Skills Online (CAN-DO)
RECRUITING · NA
-
Clinical Trial Evaluating the Efficacy of AGB101 for Reducing Hippocampal Overactivity in Older Adults
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02323581 · 520 participants · NA
Endovascular Treatment of TAAA and Aortic Arch Aneurysms Using Fenestrated and Branched Stent Grafts
- NCT04656496 · 520 participants · NA
NOURISH-T+: Promoting Healthy Eating and Exercise Behaviors
- NCT05445778 · 520 participants · Phase 3
Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
- NCT05498428 · 520 participants · Phase 2
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI